Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

GT Biopharma (GTBP) EBITDA (2016 - 2021)

GT Biopharma (GTBP) has disclosed EBITDA for 12 consecutive years, with -$18.2 million as the latest value for Q4 2021.

  • On a quarterly basis, EBITDA fell 297.65% to -$18.2 million in Q4 2021 year-over-year; TTM through Dec 2021 was -$57.5 million, a 950.31% decrease, with the full-year FY2025 number at -$12.4 million, up 13.52% from a year prior.
  • EBITDA was -$18.2 million for Q4 2021 at GT Biopharma, down from -$6.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $263.0 million in Q4 2019 to a low of -$234.7 million in Q3 2018.
  • A 5-year average of -$9.8 million and a median of -$4.4 million in 2021 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 4914.07% in 2017, then surged 126.38% in 2020.
  • GT Biopharma's EBITDA stood at -$5.9 million in 2017, then tumbled by 3883.36% to -$234.7 million in 2018, then soared by 212.09% to $263.0 million in 2019, then plummeted by 96.5% to $9.2 million in 2020, then tumbled by 297.65% to -$18.2 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's EBITDA are -$18.2 million (Q4 2021), -$6.0 million (Q3 2021), and -$4.4 million (Q2 2021).